drugset / Trial / NCT01069822

A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels

NCT01069822

Phase 1 Completed 46 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-label

Summary

The main purpose of this study is to evaluate the effect repeated doses of AZD6765 (a drug being developed for the treatment of patients with severe major depressive disorder) has on the PK (pharmacokinetic) profile of Midazolam. (The PK profile is how the drug leaves your body and acts in the body.)

Timeline

Start
2010-02
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule Oral
Subject lanicemine Small molecule Intravenous

Indications

No indication recorded.